[Clinical trials of an association of a choleretic (1-morpholinoacetyl-3-phenyl-4-oxo-1,2,3,4-tetrahydroquinazoline hydrochloride), (Rec 14-0127) and phenolphthalein and belladonna extract].
D001532:Atropa belladonna / Q000627:therapeutic use*; D002756:Cholagogues and Choleretics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005767:Gastrointestinal Diseases / Q000188:drug therapy*; D006801:Humans; D008107:Liver Diseases / Q000188:drug therapy*; D009025:Morpholines / Q000627:therapeutic use*; D010635:Phenolphthaleins / Q000627:therapeutic use*; D008517:Phytotherapy; D010919:Placebos; D010946:Plants, Medicinal; D010947:Plants, Toxic; D011799:Quinazolines / Q000627:therapeutic use*; D014397:Tuberculosis, Pulmonary / Q000150:complications
D002756:Cholagogues and Choleretics; D009025:Morpholines; D010635:Phenolphthaleins; D010919:Placebos; D011799:Quinazolines
Sperimentazione clinica su una associazione di un coleretico (1-morfolinoacetil-3-fenil-4-oxo-1,2,3,4-tetraidrochinazolina cloridrato), (Rec 14-0127) con fenolftaleina e con estratto di belladonna.